ExodusPoint Capital Management’s Entrada Therapeutics TRDA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$152K Sell
12,067
-25,363
-68% -$291K ﹤0.01% 1407
2025
Q4
$385K Buy
+37,430
New +$315K ﹤0.01% 1247
2025
Q3
Sell
-15,785
Closed -$106K 2028
2025
Q2
$106K Buy
+15,785
New +$127K ﹤0.01% 1353
2025
Q1
Sell
-16,453
Closed -$284K 1993
2024
Q4
$284K Buy
16,453
+1,113
+7% +$20.2K ﹤0.01% 1292
2024
Q3
$245K Sell
15,340
-184
-1% -$2.9K ﹤0.01% 1415
2024
Q2
$221K Buy
+15,524
New +$221K ﹤0.01% 1381

Other funds holding TRDA

ExodusPoint Capital Management's TRDA Position: Q1 2026 in Review

ExodusPoint Capital Management reduced its Entrada Therapeutics (TRDA) stake by 68% in Q1 2026, selling an estimated $291K and leaving 12,067 shares worth $152K. The position accounts for ﹤0.01% of the portfolio, ranked #1407.

ExodusPoint Capital Management first reported a position in TRDA in Q2 2024 and has held it in 6 quarters since. The position peaked at $385K in Q4 2025. 120 funds tracked by Wall St. Rank hold TRDA as of Q1 2026.

  • ExodusPoint Capital Management held 12,067 shares of Entrada Therapeutics worth $152K as of Q1 2026.
  • ExodusPoint Capital Management sold 25,363 Entrada Therapeutics shares in Q1 2026, an estimated $291K.
  • Entrada Therapeutics made up ﹤0.01% of ExodusPoint Capital Management's portfolio in Q1 2026, its #1407 holding.
  • ExodusPoint Capital Management first reported a position in Entrada Therapeutics in Q2 2024 and has held it in 6 quarters since.
  • ExodusPoint Capital Management's Entrada Therapeutics position peaked at $385K in Q4 2025.
  • 120 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.